Routes of administration

OnMi Transdermal Patches Give You Everything You Want and Nothing You Don’t

Retrieved on: 
Thursday, July 22, 2021
Health sciences, Pharmacology, Health, Routes of administration, Dosage forms, Transdermal patch, Gluten-free diet, Topical medication, Paraben, Tablet, Transdermal, Gluten

We developed transdermal patches that deliver naturally derivedvitamins and botanicals, said Ryan McFarlane, COO of OnMi.

Key Points: 
  • We developed transdermal patches that deliver naturally derivedvitamins and botanicals, said Ryan McFarlane, COO of OnMi.
  • Our transdermal patches allow ingredients to be absorbed topically without the filler ingredients that many pills and tabletscontain.
  • McFarlane said consumers might not realize that pills and tablets contain ingredients used as a lubricant for the machines that make them.
  • OnMi products, which only contain plant-based ingredients and vitamins, are also Non-GMO, Paraben Free, Dye Free, Gluten Free, and Latex Free.

IHS Announces CE Mark Certification for Proprietary Syringe Infusion System

Retrieved on: 
Thursday, July 22, 2021
Hospitals, Health, Surgery, Medical devices, Health sciences, Medicine, Dosage forms, Pharmacology, Routes of administration, Injection, Medical equipment, Infusion pump, Infusion therapy, Intravenous therapy, ISO 13485, Subcutaneous injection

Innovative Health Sciences, LLC (IHS or the Company) announced today that they have received ISO 13485 quality management system and CE mark certification for the Insignis Syringe Infusion System.

Key Points: 
  • Innovative Health Sciences, LLC (IHS or the Company) announced today that they have received ISO 13485 quality management system and CE mark certification for the Insignis Syringe Infusion System.
  • The CE mark, abbreviated for European Conformity ("Conformit Europene"), enables IHS to sell the system throughout the European Union.
  • The Insignis Syringe Infusion System is the first combination of intravenous and subcutaneous non-electric infusion pump created for use with a selectable rate flow controller, the IV Controller and the OneSett.
  • The IHS infusion system addresses nearly every infusion therapy need and can support intermittent, pause dosing, ideal for lengthy low-volume hospital infusions.

Global Topical Drug Delivery Market 2021-2026: Products, Route of Administration, End-user - Competitive Analysis, Impact of COVID-19, Ansoff Analysis - ResearchAndMarkets.com

Retrieved on: 
Monday, July 12, 2021
Health, Pharmaceutical, Health sciences, Routes of administration, Pharmacology, Medicine, Drug delivery, Route of administration, Topical medication, Transdermal, Nasal administration, Rectal administration, Dosage form

The Global Topical Drug Delivery Market is estimated to be worth USD 95.6 Billion in 2021 and is expected to reach USD 124.9 Billion by 2026, growing at a CAGR of 5.5%.

Key Points: 
  • The Global Topical Drug Delivery Market is estimated to be worth USD 95.6 Billion in 2021 and is expected to reach USD 124.9 Billion by 2026, growing at a CAGR of 5.5%.
  • Higher preference for alternative modes of drug delivery is hindering market growth.
  • Delivery of biologics through the transdermal route and self-administration and home care are some of the opportunities for the market players to grow.
  • By Route of Administration, the market is classified as Dermal Drug Delivery, Ophthalmic Drug Delivery, Rectal Drug Delivery, Vaginal Drug Delivery and Nasal Drug Delivery.

OnMi Transdermal Patches Now Available on OneLavi.com

Retrieved on: 
Friday, July 9, 2021
Health sciences, Pharmacology, Pharmaceutical sciences, Routes of administration, Dosage forms, Transdermal patch, Pharmacokinetics, Transdermal, Dermal patch, Prostate Adenocarcinoma: TransCutaneous Hormones, Sugar

PALM BEACH, FL, July 09, 2021 (GLOBE NEWSWIRE) -- American consumers, who have difficulty or dislike swallowing pills, now have easy and effective transdermal patches from OnMi available at OneLavi.com .

Key Points: 
  • PALM BEACH, FL, July 09, 2021 (GLOBE NEWSWIRE) -- American consumers, who have difficulty or dislike swallowing pills, now have easy and effective transdermal patches from OnMi available at OneLavi.com .
  • We are thrilled that OneLavi.com has chosen to offer OnMi patches to its consumers, said Ryan McFarlane, COO of OnMi, a Miami-based health and wellness company.
  • OnMi patches deliver vitamins and plant extracts without sugar and potentially harmful filler ingredients.
  • OnMi also recently introduced its transdermal patches to approximately 50 buyers from large and small retail chains in the United States.

Global $7.8 Billion Transdermal Drug Delivery Technologies/Systems Markets, 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Pharmaceutical, Health, Medical Supplies, Medical devices, Health sciences, Pharmacology, Routes of administration, Medicine, Transdermal patch, Drug delivery, TDD, Transdermal, Route of administration

The global market for transdermal drug delivery systems should grow from $6.4 billion in 2021 to $7.8 billion by 2026, at a compound annual growth rate (CAGR) of 4.2% for the period of 2021-2026.

Key Points: 
  • The global market for transdermal drug delivery systems should grow from $6.4 billion in 2021 to $7.8 billion by 2026, at a compound annual growth rate (CAGR) of 4.2% for the period of 2021-2026.
  • This report aims to provide a comprehensive study of the global market for transdermal drug delivery technologies/systems.
  • It provides a detailed description of the different types of transdermal drug delivery systems (passive and active) and the current and historical market revenues.
  • Transdermal drug delivery (TDD) is still a relative niche segment, currently accounting for a small market share in the overall drug delivery market.

Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021

Retrieved on: 
Thursday, July 1, 2021
Health sciences, Pharmacology, Routes of administration, Pharmacy, Dosage forms, Transdermal patches, Transdermal, Contraceptive patch, Patch

A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here .

Key Points: 
  • A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/ , or by clicking here .
  • Please log in approximately 10 minutes prior to the scheduled start time.
  • The archived webcast will be available in the Events and Presentations section of the company's website.
  • Twirla is based on our proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.

China Enteral Nutrition Market 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 30, 2021
Fitness & Nutrition, Health, Routes of administration, Enteral feeding, Enteral administration, Feeding tube, Health sciences, Medicine, Health

According to the analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019.

Key Points: 
  • According to the analysis, the sales value of Enteral Nutrition in China has grown steadily year by year from 2016 to 2019.
  • The CAGR of the sales value of Enteral Nutrition is about 6.5% from 2016 to 2020 in China.
  • With the improvement and popularization of medical services in China, the demand for Enteral Nutrition will continue to increase, so the sales of Enteral Nutrition in China will maintain a growing trend.
  • 2 Sales of Enteral Nutrition in China, 2016-2020
    2.3 Sales of Enteral Nutrition by Dosage Form in China, 2016-2020

Walmart.com Now Offers OnMi Transdermal Supplement Patches

Retrieved on: 
Monday, June 28, 2021
Health sciences, Pharmacology, Dosage forms, Pharmaceutical sciences, Pharmaceutical industry, Routes of administration, Transdermal patch, Tablet, Capsule, Crave

PALM BEACH, FL, June 28, 2021 (GLOBE NEWSWIRE) -- Walmart.com now offers OnMi patches for wellness, support, and relief.

Key Points: 
  • PALM BEACH, FL, June 28, 2021 (GLOBE NEWSWIRE) -- Walmart.com now offers OnMi patches for wellness, support, and relief.
  • OnMi transdermal patches stand apart from other supplements on the market because it gives you 100 percent vitamins and minerals without any filler ingredients or sugar.
  • For 40 percent of consumers in the United States who have trouble swallowing pills, tablets or capsules, OnMi patches are a solution they will love.
  • OnMi also offers Crave-Less, which helps you say no to cravings, and Hangover, which boosts yourbody's ability to bounce back.

Worldwide Enteral Nutrition Industry to 2027 - Growth in Incidence of Chronic Diseases is Driving the Market - ResearchAndMarkets.com

Retrieved on: 
Friday, June 11, 2021
Fitness & Nutrition, Health, Enteral feeding, Routes of administration, Feeding tube, Medical equipment, Enteral administration

The global enteral nutrition market was valued at $6,762 million in 2018, and is projected to reach $12,294 million by 2027, registering a CAGR of 7.1% from 2020 to 2027.

Key Points: 
  • The global enteral nutrition market was valued at $6,762 million in 2018, and is projected to reach $12,294 million by 2027, registering a CAGR of 7.1% from 2020 to 2027.
  • The enteral nutrients are administered directly into the stomach, duodenum, or jejunum of a patient via enteral pumps and enteral feeding tubes.
  • Rise in prevalence of chronic disorders such as cancer and neurological disorders is the major factor that contributes toward the growth of the enteral nutrition market.
  • However, poor demand and lack of awareness of enteral nutrition in underdeveloped countries hamper market growth.

Starton Therapeutics Advances STAR-LLD Transdermal Lenalidomide Following Successful Skin Permeation Studies

Retrieved on: 
Wednesday, June 9, 2021
Medicine, Clinical medicine, Drugs, Immunosuppressants, Aromatic amines, Routes of administration, Lenalidomide, Transdermal

With this milestone, Starton has advanced multiple formulation candidates in its transdermal lenalidomide (STAR-LLD) program into nonclinical studies.

Key Points: 
  • With this milestone, Starton has advanced multiple formulation candidates in its transdermal lenalidomide (STAR-LLD) program into nonclinical studies.
  • The invention includes a unique Method of Use with a pretreatment to modulate the outermost layer of the skin reversibly and facilitate drug uptake.
  • Using a 505(b)(2) approval path, Starton is not anticipating to have to repeat nonclinical safety studies.
  • Once target blood levels and skin tolerability are demonstrated, Starton will select a lead candidate to advance into human clinical trials.